ASY-77A / Asylia Therapeutics - LARVOL DELTA

First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models (ASH 2025) - "Additionally,77A markedly enhanced anti-tumor activity of proteosome inhibitors (bortezomib and carfilzomib),radiation, and STING agonists (diABZI and IACS-8803) in MPC11 and Vk*MYC models. 77A is a first-in-class anti-HSP70 antibody that uniquely leverages HSP70 neoantigen biology to bridgeinnate and adaptive immunity. It generates robust and durable anti-tumor activity in hematologic andsolid tumor models, and synergizes with multiple immunomodulatory and standard therapies,supporting its clinical translation as a novel immunotherapy platform."

Immunomodulating • IO biomarker • Preclinical • Breast Cancer • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor • CD4 • CD8

ASH 2025: New MD Anderson-developed antibody boosts immune response against blood cancers and solid cancers (MD Anderson Press Release) - " In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors...In laboratory models, 77A demonstrated strong antitumor effects by enhancing the activity of both innate and adaptive immune cells, including natural killer (NK) cells and T cells. The antibody improved the ability of immune cells to detect and destroy cancer cells, and it worked well in combination with other treatments, such as chemotherapy, radiation therapy and immune checkpoint blockade."

Preclinical • Lymphoma • Multiple Myeloma • Solid Tumor